Altimmune, Inc. (NASDAQ:ALT) Receives $20.00 Average Target Price from Brokerages

Altimmune, Inc. (NASDAQ:ALT) has earned a consensus recommendation of “Moderate Buy” from the eight analysts that are currently covering the company, Marketbeat.com reports. Two analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $20.00.

A number of equities analysts have recently weighed in on ALT shares. HC Wainwright reaffirmed a “buy” rating and set a $12.00 target price on shares of Altimmune in a research report on Thursday, November 14th. UBS Group started coverage on shares of Altimmune in a report on Tuesday, November 12th. They set a “buy” rating and a $26.00 price objective on the stock.

Institutional Trading of Altimmune

Several hedge funds and other institutional investors have recently modified their holdings of ALT. Geode Capital Management LLC lifted its holdings in shares of Altimmune by 4.7% during the 3rd quarter. Geode Capital Management LLC now owns 1,668,004 shares of the company’s stock worth $10,244,000 after acquiring an additional 74,194 shares during the last quarter. Bellevue Group AG lifted its position in Altimmune by 43.9% in the 3rd quarter. Bellevue Group AG now owns 863,660 shares of the company’s stock worth $5,303,000 after buying an additional 263,660 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in Altimmune by 142.9% in the second quarter. Dimensional Fund Advisors LP now owns 570,174 shares of the company’s stock worth $3,791,000 after buying an additional 335,444 shares in the last quarter. BBR Partners LLC grew its position in Altimmune by 4.5% during the second quarter. BBR Partners LLC now owns 374,784 shares of the company’s stock valued at $2,492,000 after acquiring an additional 16,271 shares during the last quarter. Finally, SG Americas Securities LLC lifted its holdings in shares of Altimmune by 542.8% in the 2nd quarter. SG Americas Securities LLC now owns 254,571 shares of the company’s stock worth $1,693,000 after acquiring an additional 214,968 shares during the last quarter. Institutional investors own 78.05% of the company’s stock.

Altimmune Price Performance

Shares of NASDAQ:ALT opened at $9.03 on Friday. The firm has a 50 day simple moving average of $7.71 and a 200 day simple moving average of $7.06. The company has a market cap of $642.26 million, a price-to-earnings ratio of -5.83 and a beta of 0.15. Altimmune has a one year low of $5.28 and a one year high of $14.84.

Altimmune (NASDAQ:ALT) last posted its earnings results on Tuesday, November 12th. The company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.35) by $0.03. The business had revenue of $0.01 million for the quarter. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. During the same quarter in the prior year, the business earned ($0.39) earnings per share. As a group, analysts expect that Altimmune will post -1.36 EPS for the current year.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.